A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
Advanced or Metastatic Solid Tumors
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 85 (final count)
- Started
- May 7, 2021
- Main results expected
- Jul 1, 2026
- Fully finished
- Jul 1, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Evaluate safety and tolerability of escalating doses of ERAS-007 BID-QW
Measured over: Assessed up to 24 months from time of first dose
Dose Limiting Toxicities (DLT)
Measured over: Study Day 1 up to Day 29
Maximum tolerated dose (MTD)
Measured over: Study Day 1 up to Day 29
Recommended dose (RD)
Measured over: Study Day 1 up to Day 29
Adverse Events
Measured over: Assessed up to 24 months from time of first dose
Plasma concentration (Cmax)
Measured over: Study Day 1 up to Day 29
Time to achieve Cmax (Tmax)
Measured over: Study Day 1 up to Day 29
Area under the curve
Measured over: Study Day 1 up to Day 29
Half-life
Measured over: Study Day 1 up to Day 29
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04866134 · record last updated 2026-09-16 · checked 2026-11-09 15:42 UTC